Andere Sprachen HUTCHMED (China) Limited Nasdaq

Aktien

A2AF74

US44842L1035

HCM

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 17.06.2024			% 5 Tage	% 1. Jan.
17.88 ^USD	-1.32%		+0.68%	-1.27%

17.06.	Hutchmed feiert "vielversprechende" Ergebnisse für Sovleplenib in China	AN
10.06.	Transcript : HUTCHMED Limited Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Hutchmed celebrates "promising" results for sovleplenib in China	17.06.
HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology	17.06.
Hutchmed (China) begins trial of menin inhibitor HMPL-506	07.06.
Hutchmed Begins Phase 1 Trial of Potential Treatment for Acute Myeloid Leukemia	07.06.
Hutchmed (China)'a Cancer Drug Phase I Clinical Trial Begins	07.06.
HUTCHMED Limited Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China	07.06.
HUTCHMED Limited Announces Results from FRUTIGA, HUTCHMED's Phase III Trial of Fruquintinib in Combination with Paclitaxel for the Treatment of Second-Line Advanced Gastric Cancer	03.06.
HUTCHMED Limited Highlights Publication of Phase III FRUTIGA Results in Nature Medicine	03.06.
HUTCHMED Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology	24.05.
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be presented at the upcoming EHA2024 Congress	20.05.
Hutchmed (China) Chairman Resigns, Successor Named	20.05.
Hutchmed China Simon To leaves role, succeeded by Dan Eldar	17.05.
Hutchmed Announces Retirement of Simon To as Chairman, Names Dan Eldar Successor	17.05.
HUTCHMED Limited Announces Executive Changes	17.05.
Hutchmed (China) to Present Sovleplenib Phase III Data at EHA2024 Congress	17.05.
HUTCHMED Limited Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to Be Presented at the Upcoming EHA2024 Congress	17.05.
Hutchmed announces trials of HMPL-306 and Surufatinib cancer therapies	14.05.
Hutchmed Starts Phase 2/3 Trial of Surufatinib Combination Therapy in Pancreatic Cancer	14.05.
HUTCHMED Limited Initiates the RAPMichael Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China	14.05.
Hutchmed Starts Phase 2/3 Trials for Pancreatic Cancer Drug in China; Shares Rise 3%	14.05.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen HUTCHMED (China) Limited Nasdaq

Aktien

A2AF74

US44842L1035

HCM

Andere Sprachen

Filter